Subcutaneous administration of immunoglobulin (IGSC) in a home setting, compared with
intravenous administration, can improve patient quality of life. During IGSC, however, the …

BACKGROUND: Subcutaneous immunoglobulin (IGSC) replacement therapy for primary
immunodeficiency (PI) is equally efficacious to intravenous immunoglobulin (IGIV), induces …

Purpose Treatment of primary immunodeficiency diseases (PIDD) with subcutaneous (SC)
infusions of IgG preceded by injection of recombinant human hyaluronidase …

Immunoglobulin (IgG) replacement therapy has been the cornerstone of treatment for
primary immunodeficiency disease for nearly 60 years. During this time, research has …

Immunoglobulin replacement therapy is a life-saving treatment in patients with
immunodeficiency and effective in the management of autoimmune disorders …

Sundin M, Nordin K, Jostemyr Y, Winiarski J. Subcutaneous IgG replacement after pediatric
SCT. Abstract: Hypogammaglobulinemia is common after pediatric SCT and IgG …

Antibody deficiency syndromes can manifest as primary or secondary immunodeficiency
diseases. Relatively few of the primary immunodeficiency diseases (PIDDs) clinically …

ENHANZE drug delivery technology, which offers a commercially validated method to
facilitate subcutaneous (SC) delivery of coadministered therapeutics, has been applied to …

This chapter will provide information on reported side effects in the literature published
during the year 2010 with regard to different types of blood and plasma products and …

'ENHANZE® drug delivery technology: Advancing subcutaneous drug delivery using
recombinant human hyaluronidase PH20'provides readers with in-depth information on the …